A Phase 2 interventional study of medrol dosepak and HYDROcodone Oral Tablet in Foot Injuries and Disorders, Ankle Injuries and Disorders and Achilles Tendon Injury, sponsored by Emory University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Emory University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Foot Injuries with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Foot Injuries · United States.
Among the 27 studies in Foot Injuries with a site in United States, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 2, and was the 22nd registered.
60 studies on the registry are indexed under Foot Injuries; 15 are open to participants now.
Browse Foot Injuries studies →9 of the 27 studies in Foot Injuries with a site in United States are open now. Recruiting first, the newest first:
Capsicure, LLC · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 13–18
Capsicure, LLC · Sites in United States
Ages 18+
University of Southern California · Sites in United States
Ages 21+
Jason Wilken · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Foot Injuries studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 46 interventional studies indexed under Foot Injuries.
Median enrollment 46 across the 21 interventional studies, 45 across the 6 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 27 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 1 study filed under Foot Injuries — fewer than ten, so there is no comparison to draw.
5 of the studies in Foot Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07701590Capsicure, LLCCAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs | 2026-12-20 |
| NCT06780202Emory UniversityAssessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients | 2027-06 |
| NCT06352788Jason WilkenFrom Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices | 2027-08-31 |
| NCT07287969University of UtahThe Safety of Reusing Walking Boot Components for Patients Recovering From Acute Foot and Ankle Injuries | 2027-09 |
| NCT04623853University of WashingtonInvestigating Auto Adjusting Dynamic AFO | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Foot Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.
The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes
The opioid epidemic continues to create a lasting impact on society, leading researchers to focus on ways to decrease opioid prescription rates and subsequently, opioid consumption. Opioid-naïve patients undergoing minor to major surgeries have been shown statistically to be largely affected.1 This includes significant numbers resulting from forefoot surgery specifically with around 6.2% of the mentioned population being at risk for new persistent opioid use.
This has provoked researchers to seek a new route that decreases exposure to opioid use through proposals for multimodal pain regimes.
A recent addition to some of these proposed treatments has been a 6-day low-dose oral methylprednisolone taper beginning on the day of surgery. This has been tested with "terrible triad" elbow injuries, distal radius fractures, and total shoulder arthroplasties with promising results showing decreased consumption of the as-needed opioid prescription. Furthermore, the results of these studies show a significant decrease in pain and increased range of motion following surgery. This is likely due to the anti-inflammatory functioning of glucocorticoids, without inhibiting the healing process.
Based upon the findings stated above, the proposed research will attempt to apply this new pain regime to foot and ankle surgeries, specifically forefoot, ankle, and Achilles surgeries, to take another step towards bettering perioperative care with opioid-free treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Emory Orthopedic patients undergoing foot and ankle surgery
Exclusion Criteria:
The group will be given Medrol Dosepak in a tapered, low-dose manner, orally once a day. Subjects will be sent home with a pain journal where they will record their pain and nausea 3 times daily starting the day of surgery and the following 7 days along with their daily hydrocodone consumption. These journals will be collected at their 2-week post-op appointment which is scheduled ± 1 week. In this appointment, subjects will also be evaluated for complications.
Drug: medrol dosepak · Drug: HYDROcodone Oral Tablet
Each subject will receive the standard pain regime of both surgeons. This includes a nerve block before surgery for pain prevention. While in surgery, the subject will receive 10 mg of dexamethasone intravenously. Post-surgery, each subject will be instructed to take vitamin C for nerve pain and vitamin D for bone healing. They will also be provided with a prescription of aspirin for deep vein thrombosis (DVT) prophylaxis, ondansetron (Zofran) for nausea, and Colace for constipation relief. Both groups will receive a prescription of 20 5 mg hydrocodone pills to be taken as needed for pain, 1 every 6 hours Subjects will be sent home with a pain journal where they will record their pain and nausea 3 times starting the day of surgery and the following 7 days along with their daily hydrocodone consumption. Journals will be collected at their 2-week post-op appointment which is scheduled ± 1 week. Subjects will also be evaluated for complications
Drug: HYDROcodone Oral Tablet
Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression. This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).
Also known as: Methylprednisolone
This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Post operative Nausea
The subjects will report nausea along the visual analog scale (VAS scale), which they will be educated on before surgery. A VAS for nausea is a straight line with one end labeled "no nausea" and the other end labeled "worst nausea imaginable". The patient marks a point on the line to indicate their nausea level. The distance from the "no nausea" end of the line is used to score the nausea intensity
Time frame: Baseline (Day 0), 7 days post op
Post operative pain
The subject will measure pain along the visual analog scale (VAS scale), which they will be educated on before surgery. A VAS for pain is a straight line with one end labeled "no pain" and the other end labeled "worst pain imaginable". The patient marks a point on the line to indicate their pain level. The distance from the "no pain" end of the line is used to score the pain intensity
Time frame: Baseline, 0.25 months, 1.5 months, 3 months, 6 months
Post operative opioid consumption
Total number of opioids consumed each day will be captured.
Time frame: Baseline (Day 0), 7 days post op
Complications due to the Medrol Dosepak
Complications will be monitored via radiographs and clinical analyses at post-operative appointments for impaired wound-healing and infection
Time frame: 1.5 months, 3 months, 6 months
Patient reported outcomes
Patient-reported outcomes will be measured along the 12-item Short Form Health Survey which measures the impact of their current health on everyday life, the Patient-Reported Outcomes Measurement Information System (PROMIS) which measures physical, mental, and social health and the VAS scale, which measures pain at rest
Time frame: Baseline (pre operative assessment), Post operation (6 months)
Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone